GlassScriptPhysician profile
Manthan Pandya
NPI 1174009849
$651.95
in general payments reported to CMS, 2019-2025
15 companies · $416 in 2025
The $416 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $76.24 · 2024: $159 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $612.39 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $124.97 | 2024-2025 | Mounjaro, Zepbound |
| Madrigal Pharmaceuticals | $82.03 | 2025 | Rezdiffra |
| Medtronic, INC. | $67.10 | 2023-2025 | Minimed 780g |
| Amryt Pharma Holdings LTD | $56.81 | 2023 | Myalept |
| Sanofi-Aventis U.S. LLC | $54.24 | 2025 | |
| Abbott Laboratories | $52.13 | 2024-2025 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $46.84 | 2025 | Isturisa |
| Corcept Therapeutics | $36.67 | 2025 | Korlym |
| Exact Sciences Corporation | $25.01 | 2025 | The Cologuard Plus Collection Kit |
| Insulet Corporation | $23.55 | 2024 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $20.78 | 2025 | |
| Merck Sharp & Dohme LLC | $17.93 | 2025 | Zerbaxa |
| Vertex Pharmaceuticals Incorporated | $16.00 | 2025 | |
| Xeris Pharmaceuticals, INC. | $14.16 | 2024 | Gvoke Hypopen |
| Novo Nordisk INC | $13.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manthan Pandya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.